4.7 Article

The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Journal

ALZHEIMERS & DEMENTIA
Volume 7, Issue 3, Pages 263-269

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2011.03.005

Keywords

Alzheimer's disease; Dementia; Diagnosis; Magnetic resonance brain imaging; Positron emission tomography; Cerebrospinal fluid

Funding

  1. Elan Pharmaceuticals
  2. Forest Pharmaceuticals
  3. Baxter Healthcare
  4. Pfizer Canada
  5. NIH
  6. Alzheimer's Association
  7. Fidelity Biosciences
  8. Baxter
  9. Pfizer Inc.
  10. Avid Radiopharmaceuticals
  11. Eli Lilly and Co.

Ask authors/readers for more resources

The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of revising the 1984 criteria for Alzheimer's disease (AD) dementia. The workgroup sought to ensure that the revised criteria would be flexible enough to be used by both general healthcare providers without access to neuropsychological testing, advanced imaging, and cerebrospinal fluid measures, and specialized investigators involved in research or in clinical trial studies who would have these tools available. We present criteria for all-cause dementia and for AD dementia. We retained the general framework of probable AD dementia from the 1984 criteria. On the basis of the past 27 years of experience, we made several changes in the clinical criteria for the diagnosis. We also retained the term possible AD dementia, but redefined it in a manner more focused than before. Biomarker evidence was also integrated into the diagnostic formulations for probable and possible AD dementia for use in research settings. The core clinical criteria for AD dementia will continue to be the cornerstone of the diagnosis in clinical practice, but biomarker evidence is expected to enhance the pathophysiological specificity of the diagnosis of AD dementia. Much work lies ahead for validating the biomarker diagnosis of AD dementia. (C) 2011 The Alzheimer's Association. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available